Mevastatin

Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment[1][2][3].

Product Specifications

CAS Number

[73573-88-3]

Product Name Alternative

Compactin; ML236B

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Apoptosis; Autophagy; Bacterial; HMG-CoA Reductase (HMGCR)

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Metabolic Disease; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/mevastatin.html

Purity

99.46

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

CC[C@H](C)C(O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@]12[H])=O

Molecular Formula

C23H34O5

Molecular Weight

390.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Sugazaki M, Hirotani H, Echigo S, et al. Effects of mevastatin on grafted bone in MRL/MpJ mice. Connect Tissue Res. 2010 Apr;51 (2) :105-12.|[2]Evangelopoulos ME, Weis J, Krüttgen A. Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR. J Neurosci Res. 2009 Jul;87 (9) :2138-44.|[3]Wächtershäuser A, et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis. 2001 Jul;22 (7) :1061-7.|[4]Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 Apr;32 (4) :980-6.